Soliris
Term · Oncology and biomedicine · MLC-T-ONC-007861
A drug used to prevent red blood cells from being destroyed in patients with a rare red blood cell disorder called paroxysmal nocturnal hemoglobinuria (PNH). It is also used to treat another rare disorder called atypical hemolytic urea syndrome (aHUS), in which blood clots form in small blood vessels. Soliris binds to an immune system protein called C5. This helps keep red blood cells from breaking down and helps keep blood clots from forming. Soliris is a type of monoclonal antibody. Also called eculizumab.
| Identifier | MLC-T-ONC-007861 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | eculizumab |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-007861",
"term": "Soliris",
"field": "Oncology and biomedicine",
"definition": "A drug used to prevent red blood cells from being destroyed in patients with a rare red blood cell disorder called paroxysmal nocturnal hemoglobinuria (PNH). It is also used to treat another rare disorder called atypical hemolytic urea syndrome (aHUS), in which blood clots form in small blood vessels. Soliris binds to an immune system protein called C5. This helps keep red blood cells from breaking down and helps keep blood clots from forming. Soliris is a type of monoclonal antibody. Also called eculizumab.",
"synonyms": [
"eculizumab"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/soliris/"
}
Record 15,167 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.